Currently trading around a penny a share Singapore Stock QT Vascular (QTVLF) is one of the most undervalued biotech/medical stocks I have ever seen! With FDA and EU approval for it’ s coronary products, a new partnership with the World&rsquo s leading medical device company, US sales booming, backed by the government of Singapore with large foreign institutional and insider ownership, received a US Congressional award, revenues projected to skyrocket (already in the millions), debt being slashed about to become cash flow positive with expansion into Europe and Asia ramping up! Crazy undervalued now, the share price is only going to rise!
QT Vascular (QTVLF) is already selling their FDA and European Union approved coronary balloon catheter’ s and other coronary angioplasty products to over 150 Hospitals in the US alone! With US sales BOOMING and projected to skyrocket, that is just the beginning! Read this entire write up and you will be stunned how EXTREMELY UNDERVALUED QT Vascular (QTVLF) is!
All due diligence posted here is verifiable and comes straight from the CEO, the company’ s filings, audited financials, website and official press releases!….
QTVLF ALSO now has full FDA clearance and has begun clinical trials on a NEW revolutionary drug-coated coronary balloon catheter that is less invasive and does not involve placing a permanent implant!
QT Vascular (QTVLF) is a global company engaged in the development and commercialization of innovative devices for the minimally invasive treatment of vascular disease without the use of permanent implants (stents).
Currently moving Near – 0.010 with Moderate Range. Stay Alert with Singapore market Movements
QT Vascular (QTVLF) HIGHLIGHTS
1-QTVLF CEO says debt at the end of 2016 was slashed by approximately US$7.8 million from US$19.2 million in 2015 to US$11.4 million. With US sales growing and the new agreement for distribution with the world&rsquo s leading medical device company global giant Medtronics CEO says debt will continue to be taken out through 2017! (Strong Buy Signal!)
2-QTVLF is backed by the Singaporean government who is fast becoming a world leader in promoting life sciences, investing heavily in firms and in the sort of infrastructure that will support the industry through it’ s state-financed biomedical sciences investment fund (BMSIF)
3-QTVLF also backed by other major established and reputable shareholders include Three Arch Partners, a healthcare fund which has internally incubated more than a dozen start-up healthcare companies AND Luminor Pacific Fund 1 is a private equity healthcare-focused fund based in Singapore approved under the Singapore government&rsquo s global investor programme.
4-QTVLF following the AWESOME new 2017 agreement with Medtronic that went into effect March 1st 2017 the company then received an offer for up to $20 MILLION CAPITAL COMMITMENT on favorable terms from US-based New York private investment group GEM GLOBAL. GEM is a USD 3.4 billion investment group having completed 372 transactions in 70 countries. (Strong Buy Signal!)
5-QTVLF CEO says they are currently selling their coronary balloon catheter’ s and other coronary angioplasty products to over 150 Hospitals in the United States alone! (Strong Buy Signal!)
6-QTVLF has filed over 40 patents filed worldwide on it’ s coronary balloon catheter’ s and other coronary angioplasty products
7-QTVLF Awards and Recognition: company received a Certificate of Special Congressional Recognition from U.S. Congressman Jerry McNerney
8-QTVLF Awards and Recognition the company subsidiary, TriReme US, was recognized by the City of Pleasanton where it is based for its ongoing contributions to the strength of the economy locally and positive impacts to the quality of life globally
9-QTVLF is the first ever Singapore based biotech medical company to receive approval US Food and Drug Administration (&ldquo FDA&rdquo ) for an interventional medical device developed in Singapore
10-QTVLF is heading towards being CASH FLOW POSITIVE, reduced loss from US$53.1 million in FY2015 to US$12.0 million in FY2016, That is phenomenal! With the new distribution agreement with the world&rsquo s leading medical device company, Medtronic complete debt elimination and massive revenue increases will continue! (Strong Buy Signal!)
11-QTVLF CEO says that US sales in 2106 of it’ s coronary products increased a WHOPPING 49% equalling an increased per sales representative efficiency of 114% (Strong Buy Signal!)
12-QTVLF PRODUCTS are in DEMAND, CEO says they working hard to increase production in support of the new distribution agreement.the world&rsquo s leading medical device company, Medtronic. (Strong Buy Signal!)
13-QTVLF CEO says that in 2016 the US remained the companies largest market, accounting for 86.9% of total revenue. Sales to Europe improved during the year. Europe accounted for 5.8% of total revenue with US$620,000 in sales, compared with US$426,000 a year ago. With the new 2017 agreement with the world&rsquo s leading medical device company, Medtronic global and European sales are forecast to substantially increase!
14-QTVLF has obtained the approval from the US Food and Drug Administration (&ldquo FDA&rdquo ) to sell an improved version of it’ s coronary angioplasty product named Chocolate® PTCA known as Chocolate XD® (Strong Buy Signal!)
15-QTVLF ALSO received full approval from the US Food and Drug Administration (&ldquo FDA&rdquo ) to begin the pivotal study of the drug-coated version of it’ s coronary angioplasty product Chocolate® PTA known as Chocolate Touch® . This is only the 4th such device to ever receive such approval by the FDA (Strong Buy Signal!)
Read More – Things Most People Don’t Know About Qt Vascular Target Price
16-QTVLF on July 31, 2017, company announced it has started enrollment in its US Food and Drug Administration (&ldquo FDA&rdquo ) pivotal clinical study. The study will evaluate the Company’ s drug-coated balloon (” DCB” ), the Chocolate Touch® , for use in superficial femoral and popliteal arteries with the intention of obtaining a US regulatory approval. The co-principal investigators of the study are Dr. Mehdi Shishehbor of the University Hospitals of Cleveland and Professor Thomas Zeller of the Heart Center in Bad Krozingen, Germany.
17-QTVLF has generated awesome positive clinical data It’ s coronary angioplasty product Chocolate PTA achieved a 0% failure rate during a human trial study on 22 patients in Germany and New Zealand for one year, and subsequent follow-ups showed no complications. Data from the first 350 patients of a separate human trial study of the Chocolate PTA in the United States showed high rates of treatment success and limb preservation. (Strong Buy Signal!)CEO says ” We are delighted with the angiographic results of Chocolate Heart&trade showing maintenance of patency at two years,” stated Eitan Konstantino, PhD, CEO of QT Vascular. ” Those patients are doing well without a stent in their heart and this is exactly what we are here for.” (Strong Buy Signal!)
CEO also said ” in keeping with our commitment to proving the clinical value of our technology, we announced the 12 month outcomes of the Chocolate Heart® First-in-Human Study, the final results of the US registry of Chocolate® PTA known as Chocolate BAR, and the final results of the Chocolate Touch® First-in-Human trial known as ENDURE. The results of all of these studies added significantly to the body of evidence supporting the unique benefits of the Chocolate® platform” (Strong Buy Signal!)
Read More – Advanced Guide to Qt Vascular Target Price
18-QTVLF In Europe has ALSO obtained CE mark clearance for Chocolate Heart® , the coronary drug-coated balloon (Strong Buy Signal!)
19-QTVLF new cutting-edge proprietary technologies: CEO on the NEW revolutionary drug-coated coronary products ” The area of peripheral arterial disease remains very much under-treated. While stents are used to treat some of these patients, there is a growing preference for therapies such as drug-coated balloons that do not involve placing a permanent implant. Sales of drug-coated balloons are estimated to have surpassed US$300 million in 2016 in the US market and the global market will surpass US$1 billion in sales by 20202. QT Vascular is well positioned to benefit from the increased adoption of drug-coated balloons. Chocolate Touch® has received full FDA clearance to begin the pivotal trial. Upon approval, this would make Chocolate Touch® only the 4th such device to be approved in the US.
The final results of Chocolate Touch® &rsquo s first-in-human trials are similar to the best-in-class devices. The Company&rsquo s recently announced a distribution agreement with Medtronic, along with the recent launch of the Group&rsquo s latest generation coronary device, Chocolate XD® , bode well for supporting our growth in FY2017.” (Strong Buy Signal!)
Read More – Signs You Work With Qt Vascular Target Price
20-QTVLF while conducting most of it’ s business in the US it is strategically located in Singapore, a hub of Asia and have access to the markets in the PRC and Japan through distribution agreements. The business-friendly environment in Singapore will allow the use Singapore as the Asian hub for the companies Asian focused marketing activities, revenues in Asia which are forecast to grow significantly with the companies new outreach into mainland ChinaThe companies top markets include the USA and growing medical device markets, especially in Europe, China, Japan and other parts of Asia. CEO says ” Our products are focused on the treatment of cardiovascular diseases, which are the number one cause of death globally, and half of all such cases are estimated to occur in Asia”
21-QTVLF expansion into mainland China, a distribution agreement with Weihai Weigao Medical Devices, Ltd. for the distribution of our peripheral products, the GliderXtreme PTA, GliderfleX PTA and Chocolate PTA coronary products in the People&rsquo s Republic of China.Weihai Weigao Medical Devices is a leading supplier of medical devices in China.Weihai Weigao has an extensive sales network comprising 25 sales offices, 38 customer liaison centers, and 170 municipal representative offices. As at the date of this report, Weihai Weigao has a total customer base of 5,159 (including 3,090 hospitals, 414 blood stations, 611 other medical units and 1,044 distributors). (Strong Buy Signal!)
22-QTVLF expansion into mainland China, QTVLF ALSO recently announced that it has signed an agreement with the Administrative Committee of Shijiazhuang High-Tech Industry Development Zone and China VAST Industrial Urban Development Company Limited to explore opportunities for cooperation in areas including, inter alia, project development, biotechnology sharing, talent exchange and fundraising. SJZ High-Tech Zone and China VAST shall provide the land for research and development within SJZ High-Tech Zone, and assist QT Vascular in obtaining capital and other resources. SJZ High-Tech Zone shall assist to present QT Vascular’ s biotechnology and its products to companies in SJZ High-Tech Zone, to explore opportunities such as joint research and development programs and the distribution of QT Vascular’ s products in China.
23-QTVLF already has a distribution agreement with Japan-based Century Medical Inc for the distribution of QTVLF products in Japan. Century Medical is one of the largest independent medical device distributors in Japan. With over 40 years experience marketing medical devices in Japan.
Read More- Greatest Moments in Qt Vascular Target Price History
24-QTVLF Top Management Executive Vice President Ms. Pizarro spent 10 years at Boston Scientific, Neurovascular Division, where she led neurovascular minimally invasive device research (intracranial implantable devices) and development projects from concept to commercialization. Prior to joining TriReme, Ms. Pizarro was the Director of Research and Development at AngioScore Inc., where she led the development of cardiovascular and peripheral devices QT Vascular (QTVLF) Company Description
QT Vascular Ltd., together with its subsidiaries, designs, assembles and distributes therapeutic solutions for the minimally invasive treatment of complex vascular diseases. The company offers coronary products, including Chocolate percutaneous transluminal coronary angioplasty (PTCA) balloon catheter to reduce vessel trauma by providing balloon inflation and Glider PTCA for the treatment of various complex lesions.
It also provides Chocolate percutaneous transluminal angioplasty (PTA) balloon catheter for the treatment of blocked arteries Chocolate Touch, a drug-coated balloon catheter GliderfleX PTA for treating distal peripheral vessels and GliderXtreme PTA balloon catheter that targets complex lesions in the distal peripheral vasculature.
The company sells its products through its direct sales team. It has operations in the United States, Singapore, Japan, Europe, China, Australia, and Hong Kong. QT Vascular Ltd. was incorporated in 2013 and is based in Singapore.
Now is the time to buy shares of QT Vascular Ltd. (QTVLF), trading near historic lows and under the radar this award-winning biotech medical company is about to become cash flow positive. With millions in revenues and debt being slashed, new funding now being offered on favorable terms, like the $20 million from Global Emerging Markets, the US-based investment group as institutions discover the value that QT Vascular Ltd. (QTVLF) presents!
Partnering up with the the world’s leading medical device company global giant Medtronic, US sales setting NEW RECORDS and BOOMING and with the company making significant headway into the Asian markets especially China you can see how EXTREMELY UNDERVALUED this biotech is trading around a penny!
When you factor in the support it receives from the country of Singapore through it’ s state-financed biomedical sciences investment fund and the huge percentage of shares that insiders and foreign institutions own it easily stands out to me as one of America’ s MOST UNDERVALUED stocks!
I do not know of any biotech stock or otherwise, that is trading around a penny that has been recognized and received an award from the US Congress and from a US City and that also has multiple products ALREADY APPROVED by both the FDA and the EU. With it’ s products already being commercialized and new cutting edge FDA trials approved and happening the share price is only going to rise from this point.